Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Equity Ratio (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Equity Ratio data on record, last reported at 0.55 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 241.63% year-over-year to 0.55; the TTM value through Dec 2025 reached 0.55, down 241.63%, while the annual FY2025 figure was 0.55, 241.63% down from the prior year.
  • Equity Ratio reached 0.55 in Q4 2025 per FHTX's latest filing, down from 0.44 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.54 in Q1 2021 and bottomed at 0.55 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.05, with a median of 0.08 recorded in 2023.
  • Peak YoY movement for Equity Ratio: skyrocketed 146.49% in 2021, then tumbled 97696.47% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.19 in 2021, then plummeted by 99.85% to 0.0 in 2022, then crashed by 97696.47% to 0.27 in 2023, then soared by 40.62% to 0.16 in 2024, then tumbled by 241.63% to 0.55 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.55 in Q4 2025, 0.44 in Q3 2025, and 0.34 in Q2 2025.